Division of Research and the Regional Offices, Kaiser Permanente Northern California, Oakland, the Sacramento Medical Center, Kaiser Permanente Northern California, Sacramento, and the Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California.
Obstet Gynecol. 2023 Nov 1;142(5):1153-1161. doi: 10.1097/AOG.0000000000005295. Epub 2023 Aug 10.
To understand pregnant patients' reasons for prenatal cannabis use and perceptions of safety, desired and undesirable health care experiences, and desired information about prenatal cannabis use and secondarily to understand racial differences in these perceptions and preferences.
We conducted a qualitative study including 18 semi-structured, race-concordant virtual focus groups with pregnant individuals who self-reported cannabis use at prenatal care entry in a large integrated health care system in Northern California from November 2021 to December 2021. The focus groups included semi-structured questions that were recorded, transcribed, and coded by the research team. Thematic analysis was used to analyze the data.
Overall, 53 participants were included; 30 self-identified, as White and 23 self-identified as Black. Participants averaged 30.3 years of age (SD 5.2 years) and were on average at 20.9 weeks of gestation at study enrollment; 69.8% reported daily cannabis use, 24.5% reported weekly cannabis use, and 5.7% reported monthly or less cannabis use at entrance to prenatal care. Although some participants quit cannabis use in early pregnancy because of concerns about potential health risks, many perceived a lack of scientific evidence or believed that prenatal cannabis use was safe. Many preferred cannabis to over-the-counter or prescription medications for treating mood, morning sickness, pain, and sleep. Participants valued open interactions with obstetricians that acknowledged their motivations for use, and they desired information about potential risks through conversations and educational materials. White and Black participants' perspectives were generally similar, but a few Black participants uniquely described concerns about racial bias related to their prenatal cannabis use.
Pregnant patients used cannabis to manage mood and medical symptoms, and many believed that prenatal cannabis use was safer than the use of prescription medications. Obstetrician-initiated, patient-centered conversations around prenatal cannabis use, advice to discontinue cannabis use during pregnancy, and exploration of willingness to switch to medically recommended interventions for pregnancy-related symptoms may benefit patients.
了解孕妇产前使用大麻的原因,以及她们对安全性、期望和不期望的医疗体验的看法,以及对产前使用大麻的相关信息的需求,并次要地了解这些看法和偏好的种族差异。
我们开展了一项定性研究,纳入了 2021 年 11 月至 12 月期间在加利福尼亚州北部一家大型综合医疗保健系统中接受产前护理时自我报告大麻使用的 18 名怀孕个体进行了 18 次种族一致的虚拟焦点小组。这些焦点小组包括研究团队记录、转录和编码的半结构化问题。采用主题分析方法对数据进行分析。
共有 53 名参与者,30 名自我认同为白人,23 名自我认同为黑人。参与者平均年龄为 30.3 岁(标准差为 5.2 岁),在研究入组时平均妊娠 20.9 周;69.8%报告每日使用大麻,24.5%报告每周使用大麻,5.7%报告每月或更少频率的大麻使用。尽管一些参与者因担心潜在健康风险而在孕早期停止使用大麻,但许多人认为缺乏科学证据或认为产前使用大麻是安全的。许多人更喜欢大麻而非非处方或处方药物来治疗情绪、晨吐、疼痛和睡眠问题。参与者重视与妇产科医生的开放互动,这些医生承认他们使用大麻的动机,他们希望通过对话和教育材料了解潜在风险。白人和黑人参与者的观点总体相似,但少数黑人参与者独特地描述了他们对与产前使用大麻相关的种族偏见的担忧。
孕妇使用大麻来控制情绪和医疗症状,许多人认为产前使用大麻比使用处方药物更安全。妇产科医生主动发起、以患者为中心的产前使用大麻对话、建议在怀孕期间停止使用大麻、以及探讨是否愿意改用医学推荐的干预措施来治疗与怀孕相关的症状,可能对患者有益。